Phase 3 Data Published in The Lancet Show Bendamustine (Levact®) Plus ... SYS-CON Media (press release) Results from the StiL NHL-1 study published in the Lancet today show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab ... |
